Changes in Tissue Potassium Amount Before and After Treatment of Primary Hyperaldosteronism Assessed by 39K-MRI

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Procedure, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Recent human studies found tissue sodium storage in patients with hyperaldosteronism that could be detected non-invasively by 23Na-MRI. Tissue sodium accumulation could be mobilized upon treatment of hyperaldosteronism. Besides, former animal studies applying chemical electrolyte analysis indicate that this aldosterone induced sodium storage might be accompanied by intracellular potassium loss. Wether such an intracellular tissue Potassium loss occurs in vivo in patients with hyperaldosteronism and if this deficiency can be corrected by treatment is unclear. The investigators will employ 39K-MR Imaging at 7Tesla to further assess this hypothesis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 95
Healthy Volunteers: t
View:

• \- Primary Hyperaldosteronism diagnosed according to the endocrinological guidelines (J Clin Endocrinology \& Metabolism, May 2016)

Locations
Other Locations
Germany
Nephrology Department, University Hospital Erlangen
RECRUITING
Erlangen
Radiology Department, University Hospital Erlangen
RECRUITING
Erlangen
Contact Information
Primary
Christoph Kopp, MD
christoph.kopp@uk-erlangen.de
+4991318539002
Backup
Armin Nagel, PhD
armin.nagel@uk-erlangen.de
+4991318525900
Time Frame
Start Date: 2018-01-01
Estimated Completion Date: 2023-12-31
Participants
Target number of participants: 10
Treatments
Experimental: Hyperaldosteronism treatment
Patients with Hyperaldosteronism will either be treated by adrenalectomy (adrenal adenoma) or receive medical treatment (Spironolactone/Eplerenone; bilateral hyperplasia) as indicated by the Endocrinological Guideline (J Clin Endocrinology \& Metabolism, May 2016). Before and after intervention tissue sodium and tissue potassium amount will be assessed by MRI.
Related Therapeutic Areas
Sponsors
Leads: University of Erlangen-Nürnberg Medical School

This content was sourced from clinicaltrials.gov